Promising combo for pancreatic cancer hits roadblock: trial ends early
NCT ID NCT03825289
First seen May 15, 2026 · Last updated May 23, 2026 · Updated 2 times
Summary
This early-stage trial tested a combination of two drugs, trametinib and hydroxychloroquine, in 25 people with advanced pancreatic cancer that could not be removed by surgery. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE PANCREATIC CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.